#1 Clinical Trials Search in Europe

Tak-280

TAK-280 is an investigational drug currently being studied in clinical trials for patients with unresectable locally advanced or metastatic cancer. This article provides an overview of the ongoing research, focusing on the safety, tolerability, and potential effectiveness of TAK-280 in treating advanced cancers that have not responded to or are intolerant to standard therapies.

Table of Contents

What is TAK-280?

TAK-280 is a new investigational drug that is currently being studied for the treatment of advanced cancers[1]. It’s important to understand that this medication is still in the early stages of research and is not yet approved for general use. The ongoing study is what’s called a “first-in-human” trial, which means it’s the first time this drug is being tested in people[1].

Who is TAK-280 for?

The current study is focusing on patients with specific types of cancer[1]:

  • Unresectable locally advanced cancer: This refers to cancer that has grown into nearby tissues and cannot be completely removed with surgery.
  • Metastatic cancer: This is cancer that has spread from its original location to other parts of the body.
Importantly, the study is looking at patients who have either not responded well to standard treatments or cannot tolerate them[1]. This means TAK-280 could potentially offer a new option for patients who have limited treatment choices.

How is TAK-280 administered?

TAK-280 is given as an intravenous (IV) infusion[1]. This means the drug is delivered directly into the bloodstream through a vein. In the current study, patients receive the infusion on specific days of each treatment cycle:

  • Days 1, 8, 15, and 22 of a 28-day cycle
Patients continue receiving these cycles until one of three things happens: their disease progresses, they experience unacceptable side effects, or they decide to withdraw from the study[1].

How is TAK-280 being studied?

The study of TAK-280 is divided into two main phases[1]:

  1. Dose-escalation phase: This initial phase aims to determine the safety of TAK-280 and find the right dose for further testing. Researchers gradually increase the dose and closely monitor patients for any side effects.
  2. Cohort-expansion phase: Once safe doses are determined, more patients are enrolled to further study the drug’s effects. This phase includes both randomized (where patients are randomly assigned to different dose levels) and non-randomized groups.
The study plans to look at TAK-280 in three different types of cancer. In one cancer type, patients will be randomly assigned to receive either a high or low dose of TAK-280. In the other two cancer types, all patients will receive the same dose[1].

What are researchers looking at in the TAK-280 study?

The researchers are investigating several important aspects of TAK-280[1]:

  • Safety: They’re closely monitoring for any side effects, especially what are called “dose-limiting toxicities” in the first 28 days of treatment.
  • How the body processes the drug: This includes how quickly the drug reaches its maximum concentration in the blood, how long it stays in the body, and how it’s cleared from the system.
  • Effectiveness: Researchers are looking at several measures of how well the drug works, including:
    • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears
    • Duration of response (DOR): How long the cancer remains controlled
    • Progression-free survival (PFS): How long patients live without their cancer getting worse
    • Overall survival (OS): How long patients live overall
  • Specific markers for prostate cancer: For patients with metastatic castration-resistant prostate cancer (mCRPC), they’re also looking at changes in PSA levels, which can indicate how well the treatment is working.

What are the potential side effects of TAK-280?

As TAK-280 is still in early stages of testing, all potential side effects are not yet known. The study is carefully monitoring for any adverse events that occur during treatment[1]. Patients in the study will be closely watched for any unexpected reactions, especially in the first 28 days of treatment. It’s important to note that all new treatments can have side effects, and part of this study’s goal is to better understand what those might be for TAK-280.

What could TAK-280 mean for cancer treatment?

While it’s too early to say for certain, TAK-280 represents a potential new option for patients with advanced cancers who have limited treatment choices[1]. If the study shows promising results, it could lead to further research and potentially a new tool in the fight against cancer. However, it’s important to remember that drug development is a long process, and many promising drugs in early studies don’t end up being approved for general use. The results of this study will help determine the future path for TAK-280.

Aspect Details
Drug Name TAK-280
Administration Intravenous (IV) infusion
Target Population Patients with unresectable locally advanced or metastatic cancer
Study Design Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study
Treatment Duration Up to 14 treatment cycles (each cycle is 28 days)
Primary Outcomes Safety, tolerability, and occurrence of adverse events
Secondary Outcomes Pharmacokinetics, overall response rate, progression-free survival, overall survival
Follow-up Period 48 weeks after the last dose
Total Study Duration Approximately 37 months

FAQ

  • What is TAK-280? TAK-280 is an experimental drug being tested in clinical trials for patients with advanced cancer that cannot be surgically removed or has spread to other parts of the body. It is given as an intravenous (IV) infusion.
  • Who is eligible for the TAK-280 clinical trial? The trial is for patients with unresectable locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Specific eligibility criteria may vary depending on the trial phase and indication.
  • How is TAK-280 administered in the clinical trial? TAK-280 is given as an intravenous (IV) infusion on Days 1, 8, 15, and 22 of a 28-day treatment cycle. Participants may receive up to 14 treatment cycles, depending on their response and tolerability.
  • What are the main goals of the TAK-280 clinical trial? The primary goals are to assess the safety and tolerability of TAK-280, determine the appropriate dosage, and evaluate its effectiveness in treating advanced cancers. The study also aims to understand how the drug behaves in the body and its potential impact on survival rates.
  • How long does the TAK-280 clinical trial last? The total duration of the study is approximately 37 months. After the last dose of the study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.

Ongoing Clinical Trials on Tak-280

  • Study of TAK-280, Tocilizumab, and Siltuximab for Patients with Advanced or Metastatic Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Unresectable: A condition where a tumor cannot be completely removed through surgery due to its location or extent.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Dose-escalation: A process in clinical trials where the dose of a drug is gradually increased to find the optimal balance between effectiveness and side effects.
  • Cohort-expansion: A phase in clinical trials where additional participants are enrolled to further study the drug at specific dose levels.
  • Dose Limiting Toxicities (DLTs): Side effects that are severe enough to prevent an increase in the dose of a drug being tested.
  • Treatment-emergent Adverse Events (TEAEs): Any unfavorable medical occurrence that appears or worsens after starting the study treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Antidrug Antibody (ADA): Antibodies produced by the body's immune system in response to a drug, which may affect its effectiveness or safety.
  • Neutralizing Antibody (NAb): Antibodies that can reduce or eliminate the effectiveness of a drug by binding to it and preventing it from working properly.

References